John T, Voysey M, Yu L M, McCarthy N, Baudin M, Richard P, Fiquet A, Kitchin N, Pollard A J
Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Vaccine. 2015 Aug 26;33(36):4579-85. doi: 10.1016/j.vaccine.2015.06.105. Epub 2015 Jul 10.
This serological follow up study assessed the kinetics of antibody response in children who previously participated in a single centre, open-label, randomised controlled trial of low-dose compared to standard-dose diphtheria booster preschool vaccinations in the United Kingdom (UK). Children had previously been randomised to receive one of three combination vaccines: either a combined adsorbed tetanus, low-dose diphtheria, 5-component acellular pertussis and inactivated polio vaccine (IPV) (Tdap-IPV, Repevax(®); Sanofi Pasteur MSD); a combined adsorbed tetanus, low-dose diphtheria and 5-component acellular pertussis vaccine (Tdap, Covaxis(®); Sanofi Pasteur MSD) given concomitantly with oral polio vaccine (OPV); or a combined adsorbed standard-dose diphtheria, tetanus, 2-component acellular pertussis and IPV (DTap-IPV, Tetravac(®); Sanofi Pasteur MSD). Blood samples for the follow-up study were taken at 1, 3 and 5 years after participation in the original trial (median, 5.07 years of age at year 1), and antibody persistence to each vaccine antigen measured against defined serological thresholds of protection. All participants had evidence of immunity to diphtheria with antitoxin concentrations greater than 0.01IU/mL five years after booster vaccination and 75%, 67% and 79% of children who received Tdap-IPV, Tdap+OPV and DTap-IPV, respectively, had protective antitoxin levels greater than 0.1IU/mL. Long lasting protective immune responses to tetanus and polio antigens were also observed in all groups, though polio responses were lower in the sera of those who received OPV. Low-dose diphtheria vaccines provided comparable protection to the standard-dose vaccine and are suitable for use for pre-school booster vaccination.
这项血清学随访研究评估了此前参与英国一项单中心、开放标签、低剂量与标准剂量白喉加强型学龄前疫苗随机对照试验的儿童体内抗体反应的动力学情况。这些儿童此前被随机分配接受三种联合疫苗之一:一种是吸附破伤风、低剂量白喉、5组分无细胞百日咳和灭活脊髓灰质炎疫苗(IPV)的联合疫苗(Tdap-IPV,Repevax(®);赛诺菲巴斯德默克公司);一种是吸附破伤风、低剂量白喉和5组分无细胞百日咳疫苗(Tdap,Covaxis(®);赛诺菲巴斯德默克公司),与口服脊髓灰质炎疫苗(OPV)同时接种;或者一种是吸附标准剂量白喉、破伤风、2组分无细胞百日咳和IPV的联合疫苗(DTap-IPV,Tetravac(®);赛诺菲巴斯德默克公司)。随访研究的血样在参与原试验后的1年、3年和5年采集(第1年的中位年龄为5.07岁),并根据确定的血清学保护阈值测量对每种疫苗抗原的抗体持久性。所有参与者在加强免疫接种五年后均有对白喉的免疫证据,抗毒素浓度大于0.01IU/mL,分别接受Tdap-IPV、Tdap+OPV和DTap-IPV的儿童中,75%、67%和79%的儿童抗毒素保护水平大于0.1IU/mL。在所有组中也观察到了对破伤风和脊髓灰质炎抗原的持久保护性免疫反应,不过接受OPV者血清中的脊髓灰质炎反应较低。低剂量白喉疫苗提供了与标准剂量疫苗相当的保护,适用于学龄前加强免疫接种。